About Us
Reboot Rx is a nonprofit focused on advancing affordable cancer treatments by repurposing generic drugs. The organization aggregates public clinical data from studies across cancer types where generic drugs were tested for new cancer indications, consults with experts to evaluate the evidence, and, where appropriate, supports additional research through partnerships. By sharing clear, unbiased data and information with clinicians, health systems, and other decision-makers, Reboot Rx supports informed review of the existing knowledge base.
Reboot Rx does not manufacture or sell drugs, and does not profit from the sale of drugs.
Our Process: Identifying the repurposing potential of 5-ARIs
We prioritized 5-alpha reductase inhibitors (5-ARIs) after a comprehensive, evidence-based evaluation of repurposing opportunities for prostate cancer.
5-ARIs are not FDA-approved for patients with prostate cancer. This page is intended for informational purposes only and is not intended to provide medical advice and should not be relied upon in that regard.
Systematic evidence synthesis
Our AI technology analyzed data from more than 16,000 published studies covering 90 non-cancer generic drugs that had been tested for treating prostate cancer.
Manual review and structured prioritization
Our team of biomedical scientists reviewed the top 24 candidates with the most promising clinical data. Each drug was assessed using our evaluation framework, which considers the:
Strength and consistency of evidence
Magnitude of unmet need
Drug accessibility and cost
Potential barriers to clinical adoption
Clinical expert input
In collaboration with urologists and oncologists, we identified 5-ARIs as a treatment to focus on based on:
Randomized controlled trial data and observational studies
Well-understood mechanism of action and biological rationale in prostate cancer
Stable drug supply, widespread availability, and low cost
Strong feasibility for near-term adoption in clinical practice
Together, these factors led us to collate the published studies and information on 5-ARIs in patients with prostate cancer on active surveillance and create this resource for healthcare professionals.
Learn more about Reboot Rx:
Subscribe to receive updates on Reboot Rx and our work on 5-ARIs.
Reboot Rx is a registered 501(c)(3) nonprofit organization. Reboot Rx does not manufacture or sell drugs, and does not profit from the sale of drugs. Information provided on the Reboot Rx website (the “Information”), available at http://rebootrx.org (the “Site”), is intended for U.S. healthcare professionals only and not intended for patients. Information available on this Site is intended for informational purposes only and is not intended to provide medical advice and should not be relied upon in that regard. Reboot Rx provides this Information as an educational resource for the benefit of the medical community. The Information on this website has not been evaluated by the Food and Drug Administration. Reboot Rx is not a medical provider or health care facility and does not practice medicine. It thus can neither diagnose any disease or disorder, nor endorse or recommend any specific medical treatments. Nothing on this Site constitutes medical advice, recommendations as to the suitability of any specific product, service or information, or diagnoses for any medical condition. Any materials made available via the Site are provided for convenience and informational purposes only. Any clinician seeking to apply or consult the content and/or derivative sources on this website must use their independent medical judgment in the context of the individual clinical circumstances to determine any patient’s care or treatment.